Study of AZD0780 to reduce heart attack and stroke risk
Part of Heart & circulation clinical trials.
This trial tests a new medication, AZD0780, to see if it helps prevent major cardiovascular events like heart attacks or strokes in people who already have heart or blood vessel disease, or are at high risk for a first event. It might be a good fit if your cholesterol isn't well-controlled despite current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a heart attack, stroke (from narrowed arteries), or leg artery procedure at least a month ago, OR you are a man over 50 or woman over 55 with high cholesterol and evidence of artery disease or high-risk diabetes.
- You are on a stable cholesterol-lowering medication (like a statin) for at least one month before the study starts.
- You do not have severely reduced kidney function, uncontrolled diabetes, or certain other medical conditions that would interfere.
- You have not used certain cholesterol-lowering drugs (like PCSK9 inhibitors) recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether clazakizumab can reduce the risk of heart attacks or strokes in people with high levels of inflammation (measured by a blood test called hsCRP) and conditions like heart disease, obesity, diabetes, high blood pressure, or kidney disease. If you qualify, you'll receive either the study drug or a placebo to see if it helps lower your risk.
This study tests an investigational weight-loss medicine called Zenagamtide for people who have heart or blood vessel disease and are overweight or obese. The goal is to see if it can reduce heart-related risks compared to a placebo (a pill with no active medicine).
This trial tests whether two medicines, a statin and colchicine, can slow or stop early heart artery plaque from growing in people who have mild plaque but no heart disease symptoms yet. It uses special CT scans to measure plaque over 2 years.
This trial studies whether dalcetrapib can lower future heart and blood-vessel risk in people who recently had an ACS (acute coronary syndrome, often a heart attack or unstable chest pain) and have a specific genetic marker. It may help people like you by targeting a risk pathway related to that genetic background.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This trial compares two very low LDL-cholesterol targets (below 1.0 vs 1.0-1.39 mmol/L) using extra medications (PCSK9 inhibitors) to see which is safer and better for people at extremely high risk of heart attacks or strokes.
Hear when a new Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.